These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 236372)

  • 1. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems II: comparative pharmacokinetics in dogs.
    Lalka D; Jusko WJ; Bardos TJ
    J Pharm Sci; 1975 Feb; 64(2):230-5. PubMed ID: 236372
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems. I. Colorimetric estimation and stability in physiological media.
    Lalka D; Bardos TJ
    J Pharm Sci; 1973 Aug; 62(8):1294-8. PubMed ID: 4737580
    [No Abstract]   [Full Text] [Related]  

  • 3. [Kinetics of accumulation and elimination of 14C-dipine, an antineoplastic drug].
    Korolev GK; Kurasova VG; Kurchatova VV
    Farmakol Toksikol; 1978; 41(4):473-80. PubMed ID: 668875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Activation of ifosfamide in man and animal].
    Brock N; Hoefer-Janker H; Hohorst HJ; Scheef W; Schneider B; Wolf HC
    Arzneimittelforschung; 1973 Jan; 23(1):1-14. PubMed ID: 4353374
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study of the pharmacokinetics of phosphemide in rats with the use of physico-chemical methods].
    Safonova TS; Presnova ZhF; Linberg LF; Chernov VA; Kuriatov NS
    Farmakol Toksikol; 1975; 38(4):491-4. PubMed ID: 1213145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
    Bachur NR; Collins JM; Kelley JA; Van Echo DA; Kaplan RS; Whitacre M
    Clin Pharmacol Ther; 1982 May; 31(5):650-5. PubMed ID: 7075113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
    Feun LG; Savaraj N; Lu K; Guo Z; Raulston LG; Benjamin RS; Fields WS; Loo TL
    J Neurooncol; 1983; 1(3):219-24. PubMed ID: 6678971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of diaziquone after three different dosage regimens.
    Bjornsson TD; Schold SC; Friedman HS; Schneider D; Falletta JM
    Cancer Treat Rep; 1985 Dec; 69(12):1383-5. PubMed ID: 4075314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
    Wampler GL; Kuperminc M; Regelson W
    Cancer Chemother Pharmacol; 1980; 4(1):49-52. PubMed ID: 7363402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alkylation of DNA in vitro by 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone (BZQ)--I.
    Butler J; Hoey BM; Ward TH
    Biochem Pharmacol; 1989 Mar; 38(6):923-7. PubMed ID: 2930592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new metabolic reaction of diaziridines by rat liver microsomes.
    Hata Y; Watanabe M
    Biochem Biophys Res Commun; 1982 May; 106(2):526-32. PubMed ID: 7104007
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxicity of aziridinylbenzoquinone administered Iv to beagle dogs.
    Hacker MP; Hong CB; McKee MJ; Unwin SE; Urbanek MA
    Cancer Treat Rep; 1982 Oct; 66(10):1845-51. PubMed ID: 7127322
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
    Egorin MJ; Bellis EH; Salcman M; Collins JM; Spiegel JF; Bachur NR
    J Neurosurg; 1984 May; 60(5):1005-13. PubMed ID: 6716135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activity and fragmentation of aziridines in microsomes.
    Hata Y; Watanabe M; Shiratori O; Takase S
    Biochem Biophys Res Commun; 1978 Feb; 80(4):911-6. PubMed ID: 637875
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure activity relationships in a series of anti-neoplastic dinitrophenyl aziridines--protein binding studies.
    Hickman JA
    Biochem Pharmacol; 1974 Oct; 23(20):2833-8. PubMed ID: 4473986
    [No Abstract]   [Full Text] [Related]  

  • 16. CB 1954 revisited. I. Disposition kinetics and metabolism.
    Workman P; White RA; Talbot K
    Cancer Chemother Pharmacol; 1986; 16(1):1-8. PubMed ID: 3940216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).
    Jarman M; Melzack DH; Ross WC
    Biochem Pharmacol; 1976 Nov; 25(22):2475-8. PubMed ID: 985569
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study of the decomposition of alkylating mutagens of the ethyleneimine series in human lymphocyte cultures].
    Kirichenko OP; Chebotarev AN; Lakovenko KN
    Biull Eksp Biol Med; 1976 May; 81(5):552-3. PubMed ID: 820384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of vincristine and alkylating agent No. 864 on rat leukemia in relation to the distribution of drugs and leukemic cells.
    Aoshima M; Sakurai Y
    Gan; 1973 Oct; 64(5):417-25. PubMed ID: 4358729
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA modifications by potential antitumour bisaziridinylquinones.
    de Mol NJ; Lusthof KJ; Decuyper J
    Biochem Pharmacol; 1988 May; 37(9):1837-8. PubMed ID: 3288218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.